Stock Market Reviews

ADVM (Adverum Biotechnologies, Inc.) News

Get the latest news, insights, and market updates on ADVM (Adverum Biotechnologies, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Eli Lilly to buy Adverum, General Dynamics stock hits new record
  Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Eli Lilly's (LLY) deal to acquire Adverum Biotechnologies (ADVM), gold miner Newmont's (NEM) cost-cutting initiatives, and General Dynamics (GD) shares moving to an all-time record high following its latest earnings results fueled by jet demand. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
  Oct 24, 2025 - $ADVM
• Top Midday Stories: Stocks Rise After Lower-Than-Expected CPI; Intel Q3 EPS, Revenue Top Expectations
  All three major US stock indexes were up in late-morning trading Friday after the latest consumer pr
  Oct 24, 2025 - $ADVM
• Lilly to Acquire Adverum Biotechnologies
  Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. ("Adverum"), including its lead product candidate, Ixo-vec.
  Oct 24, 2025 - $ADVM
• Eli Lilly to Acquire Eye Gene Therapy Developer Adverum Biotechnologies
  Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM), which is developing a therapy
  Oct 24, 2025 - $ADVM
• Eli Lilly to Acquire Adverum Biotechnologies for Up to $12.47 a Share
  Eli Lilly (LLY) has agreed to acquire Adverum Biotechnologies (ADVM) including its lead product cand
  Oct 24, 2025 - $ADVM
• Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho Says
  Adverum Biotechnologies' (ADVM) deal to be acquired by Eli Lilly (LLY) represents a likely "best pos
  Oct 24, 2025 - $ADVM
• Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year
  Key Insights Given the large stake in the stock by institutions, Adverum Biotechnologies' stock price might be...
  Oct 3, 2025 - $ADVM
• 2 Penny Stocks That Wall Street Believes Can Soar Over 200%
  Penny stocks are highly volatile, but some of them have the potential to deliver outsized returns.
  Sep 30, 2025 - $ADVM
• Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream
  MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c
  Sep 23, 2025 - $ADVM
• Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
  Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced it has notified sites that it plans to complete screening in ARTEMIS, its first
  Sep 22, 2025 - $ADVM